Moleculin Biotech, Inc. (MBRX) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
MBRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MBRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export MBRX earnings history in CSV or JSON format
Free sign-in required to download data
Moleculin Biotech, Inc. (MBRX) Earnings Overview
As of May 8, 2026, Moleculin Biotech, Inc. (MBRX) reported trailing twelve-month net income of -$24M, reflecting +82.0% year-over-year growth. The company earned $-2.02 per diluted share over the past four quarters.
Looking at the long-term picture, MBRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$748,360 in fiscal 2015.
Moleculin Biotech, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SNDX (-$243M net income, -165.6% margin), IMVT (-$464M net income), AGIO (-$423M net income, -764.0% margin), MBRX has comparable earnings metrics. Compare MBRX vs SNDX →
MBRX Earnings vs Peers
Earnings metrics vs comparable public companies
MBRX Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$34M | -54.2% | -$25M | $-28.42 | - | - |
| 2024 | -$22M | +26.9% | -$27M | $-158.00 | - | - |
| 2023 | -$30M | -2.6% | -$30M | $-376.75 | - | - |
| 2022 | -$29M | -82.6% | -$31M | $-380.50 | - | - |
| 2021 | -$16M | +8.4% | -$23M | $-221.75 | - | - |
| 2020 | -$17M | -31.4% | -$20M | $-661.00 | - | - |
| 2019 | -$13M | -11.2% | -$18M | $-729.50 | - | - |
| 2018 | -$12M | -21.1% | -$15M | $-1031.50 | - | - |
| 2017 | -$10M | -149.7% | -$9M | $-1188.00 | - | - |
| 2016 | -$4M | -424.7% | -$4M | $-899.00 | - | - |
See MBRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MBRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MBRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMBRX — Frequently Asked Questions
Quick answers to the most common questions about buying MBRX stock.
Is MBRX growing earnings?
MBRX EPS is $-2.02, with earnings growth accelerating to +82.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-24M.
What are MBRX's profit margins?
Moleculin Biotech, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are MBRX's earnings?
MBRX earnings data spans 2015-2025. The accelerating earnings trend is +82.0% YoY. Historical data enables comparison across business cycles.